Company: IMRX
Filing Date: 2025-09-25
Form Type: 424B5
Source: 0001104659-25-093438
Chunk: 20

Company: Immuneering Corp
Filing Date: 2025-09-25
Form: 424B5
Chunk 20
---
 “blue sky” laws, as a transaction by an issuer not involving a public offering. The Investor represented that it was acquiring the shares for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. Accordingly, the shares to be sold in the concurrent private placement have not been registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. Appropriate legends will be affixed to the securities issued in the concurrent private placement.

The summary above is not complete and is subject to, and qualified in its entirety by, the provisions of the Purchase Agreement, which will be filed with the SEC as an exhibit to a Current Report on Form 8-K in connection with the concurrent private placement and incorporated by reference into the registration statement of which this prospectus supplement and the accompanying prospectus form a part. Prospective investors should carefully review the terms and provisions of the Purchase Agreement for a complete description of the terms and conditions of the Purchase Agreement.

<div align='center'>S-15</div>

TABLE OF CONTENTS

### DESCRIPTION OF THE SECURITIES WE ARE OFFERING
The material terms and provisions of our Class A common stock and each other class of our securities that qualifies or limits our Class A common stock are described under the caption “Description of Capital Stock” starting on page 8of the accompanying prospectus.

<div align='center'>S-16</div>

TABLE OF CONTENTS

#### CERTAIN U.S. FEDERAL INCOME TAX CONSEQUENCES
The following discussion is a summary of certain U.S. federal income tax consequences of the purchase, ownership, and disposition of our Class A common stock issued pursuant to this offering (the “Securities”), but does not purport to be a complete analysis of all potential tax effects. For example, this discussion does not address any tax consequences to holders of a “fundamental transaction” or holders participating in the concurrent private placement as described in this prospectus supplement. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local, or non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the